MedTrace Logo

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

NCT03178825 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-11

No results posted yet for this study

Summary

This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.

Conditions

  • Vaginal Atrophy
  • Sexual Dysfunction
  • Dyspareunia
  • Vaginal Dryness
  • Chronic UTI

Interventions

DEVICE

Hybrid Fractional Laser

Consecutive and coincident fractional 2940 nm and 1470 nm lasers

Sponsors & Collaborators

  • Sciton

    lead INDUSTRY

Principal Investigators

  • Nathan Guerette, MD · The Female Pelvic Institute of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-19
Primary Completion
2020-02-25
Completion
2020-02-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03178825 on ClinicalTrials.gov